Lidak Pharm. [LDAKA] Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA]

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: chirodoc who wrote (453)	8/19/1997 10:15:00 AM
From: MCorbley	of 1115

Chirodoc This is my understanding of Lidakol vs. Zovirax: Lidakol was as effective as Zovirax CREAM, which is used in Europe. In Europe, showing equivalency with a standard therapy is an acceptable means of validating the effectiveness of a drug. Zovirax CREAM is not available in the U.S. Zovirax OINTMENT is not as good as Zovirax CREAM (and by inference Lidakol). Zovirax OINTMENT is available in the U.S., but not for Herpes cold sores. Also, in my opinion, Lidak should have no trouble creating a marketing niche for Lidakol, even if other therapies were to be available. Likdaol is the only anit-Herpes drug which is in a separate chemical class. The other drugs are all variations of a class of chemicals called nucleoside analogs. As a class, nucleoside analogs have the reputation of being heavy duty drugs for heavy duty illnesses, with heavy duty side effects if mis-prescribed. On the other hand, Lidakol (N-docosanol) and its chemical cousins have long been known to be safe. In fact, Lidak stated in their first published paper in 1991, that they were investigating N-docosanol because the lack of toxicity was already well documented. Michael

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next